GlassScriptPhysician profile
Michelle M Fiore
NPI 1073581070
$11,442.80
in general payments reported to CMS, 2019-2025
29 companies · $1,974 in 2025
The $1,974 reported for 2025 was more than what 75% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,265 · 2020: $1,763 · 2021: $1,419 · 2022: $1,323 · 2023: $1,962 · 2024: $1,738 · 2025: $1,974.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,324 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $320 · Education: $30.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,323.69 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $319.50 |
| Education | $30.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,670.57 | 2019-2025 | |
| Janssen Biotech, INC. | $1,457.75 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Lilly USA, LLC | $935.74 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Regeneron Healthcare Solutions, INC. | $749.81 | 2019-2025 | Dupixent, Libtayo |
| Pfizer INC. | $570.20 | 2019-2025 | |
| Janssen Scientific Affairs, LLC | $511.08 | 2019-2021 | |
| Genzyme Corporation | $502.92 | 2019-2025 | |
| Ucb, INC. | $495.90 | 2019-2024 | Bimzelx |
| Vyne Pharmaceuticals INC. | $417.84 | 2020-2021 | |
| Amgen INC. | $340.57 | 2020-2023 | Otezla |
| Incyte Corporation | $309.88 | 2021-2025 | Opzelura |
| Leo Pharma INC. | $277.63 | 2020-2022 | |
| Allergan, INC. | $274.48 | 2021-2022 | |
| Organon LLC | $253.32 | 2025 | Vtama |
| Galderma Laboratories, L.P. | $251.92 | 2020-2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $212.83 | 2019-2022 | |
| Merz North America, INC. | $194.41 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $170.96 | 2020-2023 | Blu-U, Odomzo |
| Dermira, INC. | $140.33 | 2019-2020 | |
| Revance Therapeutics, INC. | $113.23 | 2024-2025 | Daxxify, Daxi |
| Almirall LLC | $102.74 | 2019-2023 | Klisyri |
| Arcutis Biotherapeutics, INC. | $99.43 | 2023-2024 | Zoryve |
| Dermavant Sciences, INC. | $86.57 | 2023-2024 | Vtama |
| Mayne Pharma Commercial LLC | $79.16 | 2019-2020 | |
| Biofrontera INC. | $74.93 | 2023-2025 | Xepi, Bf-Rhodoled, Ameluz |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $72.76 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $32.50 | 2024 | Sotyktu |
| Verrica Pharmaceuticals INC. | $24.62 | 2025 | Ycanth |
| Dusa Pharmaceuticals, INC. | $18.72 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Fiore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.